Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | NQO2 | P16083 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
| ▸ | CHAT | P28329 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL29561357 | 0.98 | ALDH1A1 (0.46) | ALDH1A1CYP3A4HPGDTSHRHSD17B10 | |
| Iodide SCHEMBL21814312 | 0.98 | ALDH1A1 (0.46) | ALDH1A1CYP3A4HPGDTSHRHSD17B10 | |
| SCHEMBL13829247 | 0.85 | RAB9A (0.50) | ACHERAB9ARCE1CHAT | |
| SCHEMBL12529937 | 0.77 | NQO2 (0.60) | ALDH1A1NQO2ACHERAB9ARCE1 | |
| SCHEMBL8754514 | 0.77 | NQO2 (0.43) | ALDH1A1NQO2ACHERAB9ARCE1 | |
| SCHEMBL19121786 | 0.77 | CYP2A6 (0.50) | ALDH1A1NQO2RAB9ARCE1CHAT | |
| SCHEMBL9331979 | 0.75 | ALDH1A1 (0.48) | ALDH1A1CYP3A4HPGDTSHRHSD17B10 | |
| SCHEMBL1261956 | 0.75 | ALDH1A1 (0.48) | ALDH1A1CYP3A4HPGDTSHRHSD17B10 | |
| SCHEMBL9332720 | 0.75 | MAPT (0.51) | HPGDTSHRHSD17B10TDP1NQO2 | |
| SCHEMBL24373985 | 0.72 | NQO2 (0.40) | CYP3A4HPGDTSHRNQO2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12071409-B2 | Quinoline derived small molecule inhibitors of nicotinamide N-methyltransferase (NNMT) and uses thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS (US) | 2024-08-27 | — | — | US | disclosed |
| US-20230107256-A1 | QUINOLINE DERIVED SMALL MOLECULE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-06 | — | — | US | disclosed |
| US-11401243-B2 | Quinoline derived small molecule inhibitors of nicotinamide N-methyltransferase (NNMT) and uses thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-08-02 | — | — | US | disclosed |
| US-20200102274-A1 | QUINOLINE DERIVED SMALL MOLECULE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2020-04-02 | — | — | US | disclosed |
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | ABBOTT LABORATORIES | 2005-08-04 | — | — | US | disclosed |
| EP-0315997-B1 | Cephalosporin compounds and antibacterial agents | MEIJI SEIKA KAISHA (JP) | 1994-04-20 | — | — | EP | disclosed |
| US-5028601-A | Substituted with an amino thiazole group and a dihydroxy-pyridone group | MEIJI SAIKA KAISHA, LTD. (JP) | 1991-07-02 | — | — | US | disclosed |
| US-4971961-A | ANTIBIOTICS AS BACTERICIDES AGAINST PSEUDOMONAS | MEIJI SEIKA KAISHA, LTD. (JP) | 1990-11-20 | — | — | US | disclosed |
| EP-0289002-A2 | Novel cephalosporin compounds and antibacterial agents | MEIJI SEIKA KAISHA LTD. (JP) | 1988-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171195-A1 | P2X7 antagonists for treating neuropathic pain | P2RX3, P2RX7, P2RX1 | ALDH1A1 1730/4885CYP3A4 3130/4885HPGD 1153/4885 |
| US-20200102274-A1 | QUINOLINE DERIVED SMALL MOLECULE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF | NNMT, NAMPT, NNT | ALDH1A1 459/4885CYP3A4 823/4885HPGD 124/4885 |
| US-20230107256-A1 | QUINOLINE DERIVED SMALL MOLECULE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE (NNMT) AND USES THEREOF | NNMT, NAMPT, NNT | ALDH1A1 755/4885CYP3A4 875/4885HPGD 140/4885 |
| US-12071409-B2 | Quinoline derived small molecule inhibitors of nicotinamide N-methyltransferase (NNMT) and uses thereof | NNMT, NAMPT, NNT | ALDH1A1 755/4885CYP3A4 875/4885HPGD 140/4885 |
| US-11401243-B2 | Quinoline derived small molecule inhibitors of nicotinamide N-methyltransferase (NNMT) and uses thereof | NNMT, NAMPT, NNT | ALDH1A1 459/4885CYP3A4 823/4885HPGD 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.